DOD Toxic Exposures, Translational Research Award | W81XWH 22 TERP TRA

Opportunity Information: Apply for W81XWH 22 TERP TRA

The DOD Toxic Exposures, Translational Research Award (FY22 TERP TRA; Funding Opportunity Number W81XWH 22 TERP TRA) is a Department of Defense research funding opportunity administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA) under CFDA 12.420. It supports science and technology and other research and development projects that focus on toxic exposures and, specifically, on turning promising research findings into clinical uses. The funding mechanism can be either a grant or a cooperative agreement, and eligibility is broadly open (unrestricted) to any type of applicant organization, subject to any additional eligibility clarifications in the full announcement. The original posting date was September 21, 2022, with an original closing date of December 1, 2022, and the program anticipated making about five awards. The listed award ceiling is shown as 0, which typically signals that applicants should rely on the detailed program announcement for budget limits or that ceilings may vary by project or be specified elsewhere in the solicitation materials.

The central purpose of this award is to fund translational research that speeds up the path from toxic exposure research ideas to real-world clinical applications. The program emphasizes moving beyond basic discovery alone and toward outcomes that can be used in health care products, clinical interventions, enabling technologies, and/or clinical practice guidelines. Translational research, as framed in the announcement, is the integration of basic science and clinical observations, with an expectation that information flows in both directions: clinical insights should inform laboratory work and mechanistic studies, and laboratory findings should be shaped into approaches that can be tested, validated, and implemented in clinical settings. The opportunity also allows the use of New Approach Methodologies, reflecting openness to modern tools and methods that can improve relevance, speed, or predictive value for human outcomes.

A key requirement is clear clinical relevance to populations affected by military service and broader public health. Proposed projects should aim to advance concepts into clinical application that matters to active-duty Service Members, Veterans, other military beneficiaries, and/or the American public. Applications are expected to explain how the research plan will translate into practice, not just generate data. This means applicants should lay out how the project will bridge basic and clinical science and demonstrate that the study design is built around a credible pathway to clinical utility, such as development of a diagnostic assay, a prevention strategy, or a therapeutic approach.

The announcement places strong emphasis on impact and transition. Applicants are expected to explicitly state how the work will significantly affect toxic exposure research and/or patient care, with the intent to move outcomes into clinical practice. Proposals should describe both short-term and long-term impacts, including how the research will ultimately contribute to new treatments or therapeutics, diagnostic tests, or prevention strategies that improve quality of life for individuals who have been impacted by toxic substances or who are likely to encounter them. In practical terms, this encourages applicants to define what success looks like at multiple time horizons, such as near-term deliverables (proof-of-concept data, prototype assays, validation steps, or feasibility results) and longer-term endpoints (clinical adoption, guideline influence, or readiness for later-stage clinical evaluation).

Finally, applications must clearly articulate translational potential by identifying the project’s expected near-term and long-term outcomes or products, whether those are new knowledge, tools, or tangible materials. The proposal should explain how these outputs will address a critical problem or question in toxic exposure-related research and/or patient care, and it must align with at least one FY22 TERP Program Goal and at least one FY22 TERP Topic Area as defined in the solicitation. Overall, the award is designed for projects that can credibly connect mechanistic or methodological advances to practical clinical solutions for toxic exposure concerns, with a well-defined pathway to real-world use and meaningful benefits for military and civilian populations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Toxic Exposures, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Sep 21, 2022.
• Applicants must submit their applications by Dec 01, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 TERP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: